Navigation Links
Response Genetics Reports Second Quarter 2007 Financial Results
Date:8/19/2007

LOS ANGELES, Aug. 14 /PRNewswire-FirstCall/ -- Response Genetics, Inc. (Nasdaq: RGDX), today reported financial results for the second quarter ended June 30, 2007.

"The second quarter of 2007 was very exciting for Response Genetics, beginning with our successful initial public offering in June," said Kathleen Danenberg, President and CEO of Response Genetics. "We are very pleased by the recent developments that have since been announced. During the quarter these developments include our collaborations with Hitachi Chemical and the University of California, San Francisco, and the publication of clinical data in the Journal of Clinical Oncology that support the use of diagnostic screening for lung cancer patients. We believe these developments further validate our business strategy of using genetic information to develop diagnostic tests which will help physicians tailor treatment to the individual patient."

Financial Results for Three Months Ended June 30, 2007

Total revenue increased to $1.5 million in the second quarter of 2007 compared to $738,150 in the second quarter of 2006. This increase was primarily due to the introduction of new testing services being offered by Response Genetics to its pharmaceutical clients, and the Company's existing pharmaceutical contracts related to pharmacogenomic testing services.

Cost of revenue for the second quarter of 2007 was $1.2 million, compared with $584,230 for the second quarter of 2006. Research and development expenses were $916,793 for the second quarter of 2007, compared with $269,247 for the same period in the prior year. General and administrative expenses of $1.9 million for the second quarter of 2007 increased from $659,246 for the second qua
'/>"/>

SOURCE Response Genetics, Inc.

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system
2. FLIPR Calcium 3 Assay Kit - An Optimal No-Wash Fluorescence Calcium Indicator Reagent for Non-Optimal Calcium Responses
3. IT critical in pandemic response, but many are not paying attention
4. Quick response manufacturing and biotech
5. Wisconsin court affirms damages in Innogenetics, Abbott patent case
6. Third Wave licenses Innogenetics tech to settle lawsuit
7. Symposium examines the effect of race on genetics and disease
8. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
9. Sonic Foundry reports GAAP loss as Q2 revenues rise
10. Fiserv reports $113.5 million in Q1 profit
11. Third Wave reports net loss of $18.9M for 2006

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)..., OMAHA, Neb., Nov. 5 T... announced financial results for the quarter ended...ts are presented in the tables that follow. ,, ...net loss of $366,000 or $0.01 per share for the th...499,000 or $0.01 per share for the third quarter o...
(Date:11/5/2009)..., FREMONT, Calif., Nov. 5 /PRNewswire-FirstCall/ ...WGBS), a leading developer of state-of-the-art gen...opher Sears, Ph.D. has joined the company,s Scient...on designing and commercializing novel molecular d...ions, and on the development of computational biol...
(Date:11/5/2009)... Brooke Sanders brings a new...ne, CA (PRWEB) November 5, 2009 -- Professional Re... reprographics company is pleased to present Brook... as their graphics/PR specialist. The addition of ...sistent growth within Professional Reprographics.,...
(Date:11/4/2009)..., ,, ROCKVILLE, Md., Nov. 4 /PRNewswire/ -... company focused on next-generation antibody drug ...10 million in Series A funding from New Enterprise...ure capital firms. The capital will be used to cre...that address two or more biological targets with a...
Breaking Biology Technology:Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 2WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 3WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 4Zyngenia, Inc. Raises $10 Million in Series A Funding 2Zyngenia, Inc. Raises $10 Million in Series A Funding 3Zyngenia, Inc. Raises $10 Million in Series A Funding 4
...y insiders knowingly misrepresented the .... 18 Hagens Berman Sobol Shapiro filed a,proposed...cs Corporation,(OTC Bulletin Board: CCYG) sharehol...esented the company and chief executive officer Ga...be traded at artificially,inflated prices., The l...
... and Company,strongly objects to implications in a...e company has suppressed results of negative clini...le in The New England Journal of,Medicine (NEJM), ... how the,industry purportedly suppresses negative ... inaccurate when it comes to Prozac -- the NEJM ar...
...utics Corporation today,announced the appointment ...Alliance Management. In this role, Ms. Perrow will...opment strategy and program execution through,prod...l also serve as a,member of Alba,s executive manag...nnounce that Ms. Perrow is joining Alba in,this cr...
Other Biology Technology:Hagens Berman Sobol Shapiro: Lawsuit Filed Against CellCyte Genetics Corporation 2Hagens Berman Sobol Shapiro: Lawsuit Filed Against CellCyte Genetics Corporation 3In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement: 2In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement: 3In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement: 4Alba Therapeutics Appoints Wendy Perrow as its Vice President, Marketing and Alliance Management 2
(Date:11/4/2009)...D, Calif., Oct. 23 GenVault Corpor... management for genomic discovery, medicine and id...h.D., GenVault,s President and CEO, will be presen...e on October 26th and 27th in La Jolla, CA. ,, ...n overview of the company together with recent cus...
(Date:11/4/2009)...K, Oct. 27 Global Rainmakers, Inc....anced R&D laboratory, today announced that the...ared to actively commercialize its suite of techno... security offerings. ,, During the past four ye...lars to develop and deploy a series of core--but e...
(Date:11/4/2009)...D, Calif., Nov. 4 GenVault Corpora...rody, M.D., Ph.D., has joined its Board of Directo...r of the Salk Institute, is an acclaimed physician...g the Salk Institute, Dr. Brody served as presiden... of the National Academy of Engineering and the In...
Breaking Biology News(10 mins):GenVault Corporation to Present at the 2009 BIOCOM Investor Conference 2Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 2Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 3Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 2Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 3Martin Hensen head of e strategies UCB Germany 3A Making e marketing more than just an add on 9458 1Five Questions About Protopic 28tacrolimus 29 Ointment 13332 1Five Questions About Protopic 28tacrolimus 29 Ointment 13332 2Five Questions About Protopic 28tacrolimus 29 Ointment 13332 3Five Questions About Protopic 28tacrolimus 29 Ointment 13332 4Synthetic biology opportunities and risks 53488 1Synthetic biology opportunities and risks 53488 2Synthetic biology opportunities and risks 53488 3
...ed to exploring ways to broaden the use of clean, ...y 1 at Stanford University. , Energy Crossroads, ...ms to reduce society,s dependence on fossil fuels,...ion: Sparking Global Change." , Cathy Zoi, chief ...ection, a nonprofit organization founded by former...
...gist Stephan B. Poulter demonstrates in THE MOTHER... YOUR LIFE (Prometheus Books, $18.95) that most of...ted by our mothers or its far-reaching impact on o... the foundation from which our emotional developme...ve through adulthood. No other relationship in ou...
...ollaborative effort, researchers from Boston Unive...at deletions or mutations within the TFAP2A gene (... distinctive clefting disorder Branchio-Oculo-Faci...erized by specific skin anomalies involving the ne...l facial appearance, and frequently cleft lip and ...
Other Biology News:How your mother's emotional legacy impacts your life 2
... SYBR Green, TaqMan, LNA spiked TaqMan, MethyLight...specific primers are designed by avoiding cross ho... search results. Primer efficiency is enhanced by ...by connecting to the Mfold server. Beacon Designer...
Goat Anti-Human IL-17D Polyclonal Antibody, Unconjugated from R&D Systems
...-ADP, FHS-LVF and CVD-Diffuse We've combined our ...lters to create the world's first notch filter wit...andpass. Each filter features an excellent transmi...e filters -- with interference coatings applied to...
Agar - ULTRAPURE from GE Healthcare, formerly Amersham Biosciences
Biology Products: